Preparation of Pluronic F127 hydrogel loaded with BIF1-iRGD recombinant protein for its targeted anti-cancer effects

Zahra Tamizifar, Abbas Jafarian-Dehkordi, Somayeh Taymouri, Fatemeh Shafiee

Abstract


Background and purpose: Pluronic F127-based hydrogel is a fair formulation for increasing the protein stability and half-life without decreasing its biological activity. The present study aimed to prepare FP127 hydrogel loaded with the recombinant BIF1-iRGD protein as a new immunotoxin with targeting potential of cancer cells.

Experimental approach: BIF1-iRGD in 19% w/v of FP127 was prepared by the cold method, and its in vitro release was determined. MTT and flow-cytometry assays were performed to evaluate the cytotoxic and apoptotic effects of BIF1-iRGD and BIF1-iRGD-hydrogel against 4T1 cells. The tumor size of 4T1 Balb-C mice was evaluated, and H&E staining was used for histopathology evaluation.

Findings/Results: BIF1-iRGD release followed the first-order model. The toxicity of BIF1-iRGD was less than that in the formulation as a hydrogel after 48 and 72 h of treatment. The null hydrogel showed no toxicity compared to the untreated cells. After 24 h, cells treated with BIF1-iRGD-hydrogel and BIF1-iRGD around their 48-h IC50 value developed apoptosis at about 55% and 35%, respectively. The tumor size decreased over time in the treated mice during the 20 days after the last injection. Also, no significant difference was observed between the effectiveness of the two groups. Tumor sections of mice treated with BIF1-iRGD and BIF1-iRGD-hydrogel had necrotic parts of about 65% and 70%, respectively.

Conclusion and implications: BIF-iRGD-hydrogel showed in vivo anticancer effects with increased toxicity in comparison to the native protein. However, the investigation of protein distribution and probable cytotoxic effect on vital organs must be noted.

 


Keywords


Apoptosis; Balb-C mice; BIF-iRGD; Hydrogel; Pluronic F127.

Full Text:

PDF

References


Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17-48. DOI: 10.3322/caac.21763.

Yoon H K, Young-Seok C, Hye Sung W, Ho Jung A, Der Sheng S, Soon Uk H, et al. Stage-stratified analysis of prognostic significance of bax-interacting factor-1 expression in resected colorectal cancer. Biomed Res Int. 2013;2013:1-8.DOI: 10.1155/2013/329839.

Takahashi Y, Karbowski M, Yamaguchi H, Kazi A, Wu J, Sebti SM, et al. Loss of BIF1 suppresses Bax/Bak conformational change and mitochondrial apoptosis. Mol Cell Biol. 2005;25(21):9369-9382.

DOI: 10.1128/MCB.25.21.9369-9382.2005.

Pierrat B, Simonen M, Cueto M, Mestan J, Ferrigno P, Heim J. SH3GLB, a new endophilin-related protein family featuring an SH3 domain. Genomics. 2001;71(2):222-234.DOI: 10.1006/geno.2000.6378.

Gil1 J, Ramsey D, Szmida1 E, Leszczynski P, Pawlowski P, Bebenek M, et al. The BAX gene as a candidate for negative autophagy-related genes regulator on mRNA levels in colorectal cancer. Med Oncol. 2017;34(2): 16,1-7.DOI: 10.1007/s12032-016-0869-y.

Coppola D, Oliveri C, Sayegh Z, Boulware D, Takahashi Y, Pow-Sang J, et al. BAX-interacting factor-1 (BIF1) expression in prostate cancer. Clin Genitourin Cancer. 2008;6(2):117-121.DOI: 10.3816/CGC.2008.n.018.

Runkle KB, Meyerkord CL, Desai NV, Takahashi Y, Wang HG. BIF1 suppresses breast cancer cell migration by promoting EGFR endocytic degradation. Cancer Biol Ther. 2012;13(10):956-966.DOI: 10.4161/cbt.20951.

Naik A, Al-Yahyaee A, Abdullah N, Sam JE, Al-Zeheimi N, Yaish MW, et al. Neuropilin-1 promotes the oncogenic Tenascin-C/integrin β3 pathway and modulates chemoresistance in breast cancer cells. BMC Cancer. 2018;18(1):533,1-14.DOI: 10.1186/s12885-018-4446-y.

Ghobadi M, Shafiee F. Recombinant production of BIF1-iRGD fusion protein with cytotoxic and apoptotic effects against breast cancer cell lines. Biomed Res Ther. 2026. In press.

Lyu Y, Azevedo HS. Supramolecular hydrogels for protein delivery in tissue engineering. Molecules. 2021;26(4):873,1-31.DOI: 10.3390/molecules26040873.

Thang NH, Chien TB, Cuong DX. Polymer-based hydrogels applied in drug delivery: an overview. Gels. 2023;9(7):523,1-38.DOI: 10.3390/gels9070523.

Chai Q, Jiao Y, Yu X. Hydrogels for biomedical applications: their characteristics and the mechanisms behind them. Gels. 2017;3(1):6,1-15.DOI: 10.3390/gels3010006.

Fan R, Cheng Y, Wang R, Zhang T, Zhang H, Li J, Song S, et al. Thermosensitive hydrogels and advances in their application in disease therapy. Polymers (Basel). 2022;14(12):2379,1-21.DOI: 10.3390/polym14122379.

Cui N, Dai CY, Mao X, Lv X, Gu Y, Lee ES, et al. Poloxamer-based scaffolds for tissue engineering applications: a review. Gels. 2022;8(6):360,1-24.DOI: 10.3390/gels8060360.

Liu Y, Lu WL, Wang JC, Zhang X, Zhang H, Wang XQ, et al. Controlled delivery of recombinant hirudin based on thermo-sensitive Pluronic F127 hydrogel for subcutaneous administration: in vitro and in vivo characterization. J Control Release. 2007;117(3):387-395.DOI: 10.1016/j.jconrel.2006.11.024.

Hamid Akash MS, Rehman K, Li N, Gao JQ, Sun H, Chen S. Sustained delivery of IL-1Ra from pluronic F127-based thermosensitive gel prolongs its therapeutic potentials. Pharm Res. 2012;29(12):3475-3485.DOI: 10.1007/s11095-012-0843-0.

Nasir F, Iqbal Z, Khan A, Khan JA, Khan A, Khuda F, et al. Development and evaluation of pluronic- and methylcellulose-based thermoreversible drug delivery system for insulin. Drug Dev Ind Pharm. 2014;40(11):1503-1508.DOI: 10.3109/03639045.2013.831441.

Shafiee F, Rabbani M, Behdani M, Jahanian-Najafabadi A. Expression and purification of truncated diphtheria toxin, DT386, in Escherichia coli: an attempt for production of a new vaccine against diphtheria. Res Pharm Sci. 2016;11(5):428-434. DOI: 10.4103/1735-5362.192496.

Shafiee F, Yazdani A. Recombinant production of interleukin-1 receptor antagonist in fusion to albumin binding domain with potential affinity to human serum albumin. Res Pharm Sci. 2024;19(3): 356-365.DOI: 10.4103/RPS.RPS_41_23.

Severino P, Andreani T, Jäger A, Chaud MV, Santana MH, Silva AM, et al. Solid lipid nanoparticles for hydrophilic biotech drugs: optimization and cell viability studies (Caco-2 & HEPG-2 cell lines). Eur J Med Chem. 2014;81:28-34. DOI: 10.1016/j.ejmech.2014.04.084.

Karimi Z, Taymouri S, Minaiyan M, Mirian M. Evaluation of thermosensitive chitosan hydrogel containing gefitinib loaded cellulose acetate butyrate nanoparticles in a subcutaneous breast cancer model. Int J Pharm. 2022;624:122036. DOI: 10.1016/j.ijpharm.2022.122036.

Sun D, Zhu L, Zhao Y, Jiang Y, Chen L, Yu Y, et al. Fluoxetine induces autophagic cell death via eEF2K-AMPK-mTOR-ULK complex axis in triple negative breast cancer. Cell Prolif. 2018;51(2):e12402, 1-10.DOI: 10.1111/cpr.12402.

Kim J, Francis DM, Thomas SN. In Situ crosslinked hydrogel depot for sustained antibody release improves immune checkpoint blockade cancer immunotherapy. Nanomaterials (Basel). 2021;11(2):471,1-10.DOI: 10.3390/nano11020471.

Zou S, He Q, Wang Q, Wang B, Liu G, Zhang F, et al. Injectable nanosponge-loaded Pluronic F127 hydrogel for pore-forming toxin neutralization. Int J Nanomedicine. 2021;16:4239-4250.DOI: 10.2147/IJN.S315062.


Refbacks

  • There are currently no refbacks.


Creative Commons LicenseThis work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.